Claims

1. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of depression or anxiety disease in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events.

2. 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof according to claim 1 which is the hydrobromide salt.

3. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of depression or anxiety in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events.

4. The use according to claim 3, wherein said pharmaceutically acceptable salt is the hydrobromide salt.

Claims

1. Use of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of depression or anxiety in a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased (or has to be ceased) due to weight related adverse events, wherein said medicament is intended for administration for a treatment period above 12 weeks.

2. The use according to claim 1, wherein said pharmaceutically acceptable salt is the hydrobromide salt.